David Michael Schuster MD

Radiology•Atlanta, GA

Nuclear Cardiology, Nuclear Medicine, Nuclear Radiology

Professor, Radiology & Imaging Sciences, Emory University School of Medicine

Join to View Full Profile

PO Box# 1364Atlanta, GA 30322
Phone+1 404-712-4859

Education & Training

Tufts Medical CenterResidency, Radiology-Diagnostic, 1988 - 1992
Albany Medical CenterInternship, Internal Medicine, 1987 - 1988
Albany Medical CollegeClass of 1987

Certifications & Licensure

GA State Medical License 1996 - 2027
NC State Medical License 1998 - 2026
MA State Medical License 1988 - 1997
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology
American Board of Radiology Nuclear Radiology

Clinical Trials

FACBC PET/CT for Recurrent Prostate Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE2
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer Start of enrollment: 2008 Apr 01
Terminated
Phase 2
Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas Start of enrollment: 2012 Aug 01
Completed
Not Applicable
FACBC Outcomes for Post Prostatectomy Start of enrollment: 2012 Sep 01
Completed
Phase 2, Phase 3
FACBC for Recurrent Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
FACBC for Head and Neck Cancers Start of enrollment: 2015 May 01
Withdrawn
Early Phase 1
Fusion Targeted Biopsy of the Prostate Start of enrollment: 2013 Sep 01
Completed
Not Applicable
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer Start of enrollment: 2021 Jul 16
COMPLETED
PHASE1
Roles: Contact, Principal Investigator
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy Start of enrollment: 2022 Apr 28
COMPLETED
EARLY_PHASE1
Roles: Contact
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes Start of enrollment: 2019 May 10
Active, not recruiting
Phase 2
Roles: Contact
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer Start of enrollment: 2023 Nov 29
RECRUITING
PHASE1
Roles: Principal Investigator
F18-MHF: Orthopedic Implants-Associated Infection Detection Start of enrollment: 2024 Nov 04
RECRUITING
Roles: Contact, Principal Investigator
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients Start of enrollment: 2024 Jul 25
RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven ap...
Faisal Saeed, Jacob E Berchuck, Mehmet Asim Bilen, Jatin S Gandhi, Bassel Nazha
Cancer. 2025-08-15
Volumetric Changes and Acute Toxicity withGa Prostate-Specific Membrane Antigen vsF-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Random...
Vishal R Dhere, David M Schuster, Subir Goyal, Eduard Schreibmann, Nikhil T Sebastian
Practical Radiation Oncology. 2025-07-28
Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review.
Soroush Rais-Bahrami, Phillip Davis, Albert Chau, Samuel J Galgano, Brian F Chapin
Diagnostics. 2025-05-13

Journal Articles

Imaging of Prostate Cancer Using Fluciclovine
David Schuster, MD, ScienceDirect

Authored Content

Y90 Radioembolization Dosimetry Using a Simple Semi-Quantitative Method in Intrahepatic Cholangiocarcinoma: Glass Versus Resin MicrospheresJanuary 2018

Press Mentions

Radiotracer Use Boosts Prostate Cancer OutcomesMay 14th, 2021
Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial Using Advanced Imaging of Prostate Cancer for RadiotherapyMay 30th, 2019
FDA Approves Emory-Developed Prostate Cancer Imaging ProbeJune 1st, 2016
Join now to see all

Grant Support

Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer OutcomesEMORY UNIVERSITY2019–2025
Anti-[18 F] Facbc PET-CT For Characterization Of Primary Prostate CarcinomaNational Cancer Institute2008–2011
18f-Facbc PET-CT For The Detection And Staging Of Recurrent Prostate CarcinomaNational Cancer Institute2007–2011

David Michael Schuster MD

Dr. Schuster is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Authored Content

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.